{"id":"acam2000-smallpox-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the introduction of a live, attenuated smallpox virus to the body, which triggers an immune response and provides immunity against smallpox. The vaccine is administered through multiple subcutaneous injections.","oneSentence":"ACAM2000 Smallpox Vaccine works by stimulating an immune response to the smallpox virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:35.578Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of smallpox"}]},"trialDetails":[{"nctId":"NCT05879965","phase":"","title":"Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-10-06","conditions":"Monkeypox","enrollment":345},{"nctId":"NCT02743455","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-05","conditions":"Yellow Fever, Yellow Fever Immunisation","enrollment":92},{"nctId":"NCT06366672","phase":"EARLY_PHASE1","title":"Evaluating the Human Immune Response to the JYNNEOS Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-06-10","conditions":"Vaccinia, Virus Diseases","enrollment":20},{"nctId":"NCT00437021","phase":"PHASE1, PHASE2","title":"MVA Post-Event: Administration Timing and Boost Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-04-16","conditions":"Smallpox","enrollment":226},{"nctId":"NCT07093489","phase":"","title":"Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-09-30","conditions":"Mpox (Monkeypox), Mpox","enrollment":11990},{"nctId":"NCT06223919","phase":"PHASE3","title":"Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2023-12-16","conditions":"Monkeypox","enrollment":8686},{"nctId":"NCT07054697","phase":"PHASE4","title":"Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Aditi Chadha","startDate":"2017-01-01","conditions":"Autism Spectrum Disorder (ASD)","enrollment":54},{"nctId":"NCT05745987","phase":"PHASE4","title":"Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT","status":"RECRUITING","sponsor":"McMaster University","startDate":"2024-09-17","conditions":"Monkeypox","enrollment":3000},{"nctId":"NCT00879762","phase":"PHASE2","title":"High Dose IMVAMUNE® in Vaccinia-Naive Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-05-29","conditions":"Smallpox","enrollment":91},{"nctId":"NCT04957485","phase":"PHASE2","title":"Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS","status":"ACTIVE_NOT_RECRUITING","sponsor":"SIGA Technologies","startDate":"2022-04-05","conditions":"Smallpox","enrollment":100},{"nctId":"NCT02977715","phase":"PHASE3","title":"JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-02-23","conditions":"Monkeypox Virus Infection","enrollment":1600},{"nctId":"NCT05522296","phase":"","title":"Break-through Infection Following Mpox vaccinatIon","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2022-09-12","conditions":"Mpox","enrollment":3125},{"nctId":"NCT00928577","phase":"","title":"Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2008-12","conditions":"Smallpox","enrollment":14108},{"nctId":"NCT01158157","phase":"PHASE3","title":"VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2010-09-13","conditions":"Smallpox Vaccine Adverse Reaction","enrollment":25},{"nctId":"NCT00053495","phase":"PHASE2","title":"Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2003-01","conditions":"Smallpox","enrollment":353},{"nctId":"NCT01540929","phase":"","title":"Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-09","conditions":"Smallpox","enrollment":5001},{"nctId":"NCT01395082","phase":"","title":"ACAM2000® Myopericarditis Registry","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2011-04","conditions":"Myocarditis, Pericarditis","enrollment":24},{"nctId":"NCT00053482","phase":"PHASE2","title":"Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2003-01","conditions":"Smallpox","enrollment":357},{"nctId":"NCT00927719","phase":"","title":"Safety Surveillance Study of ACAM2000® Vaccinia Vaccine","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2008-12","conditions":"Smallpox","enrollment":897227},{"nctId":"NCT02443623","phase":"PHASE4","title":"VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2015-09","conditions":"Smallpox Vaccine Adverse Reaction","enrollment":3032},{"nctId":"NCT04410874","phase":"PHASE1, PHASE2","title":"Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer","status":"TERMINATED","sponsor":"Ivan Litvinov","startDate":"2020-11-16","conditions":"Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma","enrollment":1},{"nctId":"NCT05513313","phase":"","title":"Assessment of Myocarditis After Replication-Deficient Smallpox Immunization","status":"NOT_YET_RECRUITING","sponsor":"Womack Army Medical Center","startDate":"2029-03","conditions":"Myopericarditis, Small Pox","enrollment":2350},{"nctId":"NCT05846243","phase":"PHASE2, PHASE3","title":"Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2021-10-01","conditions":"Smallpox, Monkeypox, Cowpox","enrollment":334},{"nctId":"NCT05762523","phase":"PHASE1","title":"Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2019-05-18","conditions":"Smallpox, Monkeypox, Cowpox","enrollment":60},{"nctId":"NCT00001043","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":20},{"nctId":"NCT00006630","phase":"PHASE1","title":"Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Healthy, Communicable Diseases","enrollment":""},{"nctId":"NCT00000767","phase":"PHASE1","title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT03699124","phase":"PHASE3","title":"Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2019-06-19","conditions":"Smallpox","enrollment":1129},{"nctId":"NCT00914732","phase":"PHASE2","title":"Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-02","conditions":"Smallpox","enrollment":523},{"nctId":"NCT01668537","phase":"PHASE2","title":"A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2013-03","conditions":"Smallpox","enrollment":651},{"nctId":"NCT02038881","phase":"PHASE2","title":"Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2014-04-28","conditions":"Smallpox","enrollment":87},{"nctId":"NCT03745131","phase":"","title":"Cohort Study of Healthcare Workers Receiving Imvanex®","status":"COMPLETED","sponsor":"Public Health England","startDate":"2018-10-30","conditions":"Monkeypox","enrollment":120},{"nctId":"NCT00325975","phase":"","title":"Immune Responses to Smallpox Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-02-04","conditions":"Smallpox Vaccine","enrollment":69},{"nctId":"NCT01913353","phase":"PHASE3","title":"A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2015-03","conditions":"18-42 Year Old Healthy Vaccinia-naïve Subjects","enrollment":440},{"nctId":"NCT00316524","phase":"PHASE2","title":"A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2006-04","conditions":"Smallpox","enrollment":745},{"nctId":"NCT00857493","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2009-06","conditions":"Smallpox","enrollment":120},{"nctId":"NCT00189956","phase":"PHASE2","title":"Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2003-04","conditions":"Smallpox","enrollment":165},{"nctId":"NCT00189917","phase":"PHASE1","title":"Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2004-04","conditions":"Dermatitis, Atopic, Hay Fever","enrollment":60},{"nctId":"NCT00316602","phase":"PHASE2","title":"A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2006-07","conditions":"Atopic Dermatitis","enrollment":632},{"nctId":"NCT00316589","phase":"PHASE2","title":"Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2006-06","conditions":"HIV Infections","enrollment":581},{"nctId":"NCT01144637","phase":"PHASE3","title":"A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2013-02","conditions":"Smallpox","enrollment":4005},{"nctId":"NCT01827371","phase":"PHASE2","title":"Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-06","conditions":"Smallpox","enrollment":435},{"nctId":"NCT00133575","phase":"PHASE1, PHASE2","title":"ACAM 3000 MVA at Harvard Medical School","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Smallpox","enrollment":72},{"nctId":"NCT00082446","phase":"PHASE1","title":"Combination Study With MVA BN and Dryvax","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-05","conditions":"Smallpox","enrollment":91},{"nctId":"NCT00050505","phase":"PHASE2","title":"Expanded Dryvax Dilution Study in Previously Vaccinated Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-10","conditions":"Smallpox","enrollment":927},{"nctId":"NCT00466245","phase":"PHASE2","title":"Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-07","conditions":"Smallpox","enrollment":590},{"nctId":"NCT00053508","phase":"PHASE2","title":"Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2002-09","conditions":"Smallpox","enrollment":274},{"nctId":"NCT00282581","phase":"PHASE1","title":"Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"HIV Infections, Smallpox","enrollment":2},{"nctId":"NCT00389103","phase":"PHASE1","title":"Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)","status":"WITHDRAWN","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Smallpox, Atopic Dermatitis","enrollment":""},{"nctId":"NCT00079820","phase":"PHASE1","title":"Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-04","conditions":"Smallpox","enrollment":110},{"nctId":"NCT01056770","phase":"PHASE3","title":"Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-10","conditions":"Smallpox","enrollment":88},{"nctId":"NCT00565929","phase":"PHASE1","title":"Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-09","conditions":"Variola Major (Smallpox)","enrollment":24},{"nctId":"NCT00607243","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of CJ-50300 in Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2008-01","conditions":"Smallpox","enrollment":123},{"nctId":"NCT01317238","phase":"PHASE3","title":"Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-10","conditions":"Smallpox","enrollment":145},{"nctId":"NCT00189904","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2005-07","conditions":"HIV Infections","enrollment":151},{"nctId":"NCT00998543","phase":"","title":"A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Smallpox","enrollment":147},{"nctId":"NCT00258947","phase":"PHASE2","title":"Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-09","conditions":"Smallpox, Poxvirus Infection","enrollment":230},{"nctId":"NCT00042094","phase":"PHASE1","title":"Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®","status":"COMPLETED","sponsor":"DynPort Vaccine Company LLC, A GDIT Company","startDate":"2002-03","conditions":"Smallpox","enrollment":350},{"nctId":"NCT00068198","phase":"PHASE1","title":"Human Immune Responses Smallpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Smallpox","enrollment":45},{"nctId":"NCT00038987","phase":"PHASE1, PHASE2","title":"Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-05","conditions":"Smallpox","enrollment":330},{"nctId":"NCT00026611","phase":"PHASE2","title":"A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Smallpox","enrollment":""},{"nctId":"NCT00050518","phase":"PHASE2","title":"APSV in Vaccinia Naive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Smallpox","enrollment":444},{"nctId":"NCT00032708","phase":"PHASE2","title":"Dryvax Dilution-Prev Vacc Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-04","conditions":"Smallpox","enrollment":90},{"nctId":"NCT00046397","phase":"PHASE1","title":"Phase I Trial of Smallpox Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-09","conditions":"Healthy","enrollment":195},{"nctId":"NCT00053742","phase":"PHASE1","title":"Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-02","conditions":"Healthy","enrollment":80},{"nctId":"NCT00002261","phase":"PHASE1","title":"A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00336635","phase":"PHASE1","title":"Safety and Immunogenicity of CJ-50300","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2006-06","conditions":"Smallpox","enrollment":24},{"nctId":"NCT00103584","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers","status":"UNKNOWN","sponsor":"VaxGen","startDate":"2004-10","conditions":"Smallpox","enrollment":150},{"nctId":"NCT00189969","phase":"PHASE1","title":"Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2003-09","conditions":"Smallpox","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACAM2000®"],"phase":"phase_2","status":"active","brandName":"ACAM2000 Smallpox Vaccine","genericName":"ACAM2000 Smallpox Vaccine","companyName":"Emergent BioSolutions","companyId":"emergent-biosolutions","modality":"Biologic","firstApprovalDate":"","aiSummary":"ACAM2000 Smallpox Vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It has been studied in clinical trials for conditions including smallpox, monkeypox, and cowpox, and has been used in a dose of 10^6 PFU.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}